EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A digital twin of glimepiride for personalized and stratified diabetes treatment

Michelle Elias, Matthias König

Frontiers in Pharmacology · 08.10.2025 · 16

DOI: 10.3389/fphar.2025.1686415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.10.2025. Verfasst von Michelle Elias und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Science, Institute for Biology, Systems Medicine of the Liver, Humboldt-Universität zu Berlin, Berlin, Germany. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Optimizing glimepiride therapy for type 2 diabetes (T2DM) is challenged by pronounced inter-individual variability in pharmacokinetics.

Methods

We developed a whole-body physiologically based pharmacokinetic (PBPK) model as a digital twin of glimepiride, enabling systematic evaluation of how patient-specific factors influence drug disposition. Using curated data from 20 clinical studies, the digital twin mechanistically simulates glimepiride’s absorption, distribution, metabolism, and excretion (ADME). It accounts for key determinants of variability including renal and hepatic function, CYP2C9 genotype, and bodyweight.

Results

The model accurately reproduced observed pharmacokinetics and quantified these factors’ impact on drug exposure. Increased glimepiride exposure was predicted in individuals with hepatic dysfunction or specific CYP2C9 variants, highlighting substantial genetic and physiological effects.

Discussion

This digital twin provides mechanistic insights into pharmacokinetic variability and serves as an in silico platform for exploring individualized dosing and patient stratification strategies, laying the foundation for clinical decision support tools to improve T2DM management.

Schlagwörter

Stichwörter der Autor:innen

PBPKdiabetesdigital twinglimepiridepersonalized medicinepharmacokineticsphysiologically based pharmacokinetic model

Autor:innen und Institutionen

  • Faculty of Life Science, Institute for Biology, Systems Medicine of the Liver, Humboldt-Universität zu Berlin, Berlin, Germany.

Zitieren

APA

Elias, M., & König, M. (2025). A digital twin of glimepiride for personalized and stratified diabetes treatment. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1686415

Vancouver

Elias M, König M. A digital twin of glimepiride for personalized and stratified diabetes treatment. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1686415

BibTeX
@article{Elias2025,
  author = {Elias, Michelle and König, Matthias},
  title = {A digital twin of glimepiride for personalized and stratified diabetes treatment},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1686415}
}
Kostenlos starten →